Cargando…

Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial

OBJECTIVE: Design a feasible study to assess the efficacy and safety of Craniosacral therapy (CST) in the treatment of migraine, using a rigorous and innovative randomized controlled study design involving complementary light-touch sham treatments (CLST) as an attention control intervention. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Guangya, Ma, Saichao, Zhao, Jinfeng, Zhang, Ming, Li, Yan, Chen, Wenli, Cui, Lin, Jia, Liuyun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637508/
https://www.ncbi.nlm.nih.gov/pubmed/37960717
http://dx.doi.org/10.1097/MD.0000000000035431
_version_ 1785146513150705664
author Jiang, Guangya
Ma, Saichao
Zhao, Jinfeng
Zhang, Ming
Li, Yan
Chen, Wenli
Cui, Lin
Jia, Liuyun
author_facet Jiang, Guangya
Ma, Saichao
Zhao, Jinfeng
Zhang, Ming
Li, Yan
Chen, Wenli
Cui, Lin
Jia, Liuyun
author_sort Jiang, Guangya
collection PubMed
description OBJECTIVE: Design a feasible study to assess the efficacy and safety of Craniosacral therapy (CST) in the treatment of migraine, using a rigorous and innovative randomized controlled study design involving complementary light-touch sham treatments (CLST) as an attention control intervention. METHODS: This was a single-center, randomized, cross-over placebo-controlled experimental design. A total of 87 participants who suffered migraine attacks from 4 to 9 per month were randomly assigned into either 2 weekly units of CST or CLST for 4 weeks. And then the 2 groups were crossed and continued treatment for 4 weeks plus a follow-up observation for 4 weeks. As the primary outcome measures, Headache Impact Test-6 (HIT-6) and headache frequency were assessed every 4 weeks (at baseline, week 4, week 8 and week 12). The secondary outcome was the scores of Headache Disability inventory (HDI) and the Hamilton Anxiety Scale (HAMA) as well as the adverse events. RESULTS: All 87 individuals had been screened for eligibility, of which 60 were licensed for the study. The difference of HIT-6 and headache frequency between the 2 groups was not significant at the baseline. But the headache frequency and HIT-6 of 2 groups were all declined respectively after the CST at week 4 (group A) and week 8 (group B) than before (P(☆)= 0.01 < 0.05, 95% CI, −3.06 to −1.87; P(※)= 0.01 < 0.05, 95% CI, −3.52 to −2.53; P(1A) = 0.01 < 0.05, 95% CI, 4.55–11.7; P(2B) = 0.01 < 0.05, 95% CI, −11.78 to −6.01) while the changes were not obvious after CLST with previous treatment. The scores and frequency of fourth evaluation showed that there was no significant increase or decrease in both the 2 groups. Besides, we found that the mean scores of HIT-6 for all participants, compared with the baseline, were decreased significantly after the 3 round treatments (P(3A) = 0.01 < 0.05, 95% CI, −13.12 to −6.4; P(3B) = 0.01 < 0.05, CI, −12.73 to −6.69). We also showed the similar result in the scores of HDI and HAMA. CONCLUSION: The results indicated that standardized CST was both effective and safe in alleviating the migraine intensity and frequency as well as the headache-related disability. Further larger research is needed.
format Online
Article
Text
id pubmed-10637508
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106375082023-11-15 Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial Jiang, Guangya Ma, Saichao Zhao, Jinfeng Zhang, Ming Li, Yan Chen, Wenli Cui, Lin Jia, Liuyun Medicine (Baltimore) 5300 OBJECTIVE: Design a feasible study to assess the efficacy and safety of Craniosacral therapy (CST) in the treatment of migraine, using a rigorous and innovative randomized controlled study design involving complementary light-touch sham treatments (CLST) as an attention control intervention. METHODS: This was a single-center, randomized, cross-over placebo-controlled experimental design. A total of 87 participants who suffered migraine attacks from 4 to 9 per month were randomly assigned into either 2 weekly units of CST or CLST for 4 weeks. And then the 2 groups were crossed and continued treatment for 4 weeks plus a follow-up observation for 4 weeks. As the primary outcome measures, Headache Impact Test-6 (HIT-6) and headache frequency were assessed every 4 weeks (at baseline, week 4, week 8 and week 12). The secondary outcome was the scores of Headache Disability inventory (HDI) and the Hamilton Anxiety Scale (HAMA) as well as the adverse events. RESULTS: All 87 individuals had been screened for eligibility, of which 60 were licensed for the study. The difference of HIT-6 and headache frequency between the 2 groups was not significant at the baseline. But the headache frequency and HIT-6 of 2 groups were all declined respectively after the CST at week 4 (group A) and week 8 (group B) than before (P(☆)= 0.01 < 0.05, 95% CI, −3.06 to −1.87; P(※)= 0.01 < 0.05, 95% CI, −3.52 to −2.53; P(1A) = 0.01 < 0.05, 95% CI, 4.55–11.7; P(2B) = 0.01 < 0.05, 95% CI, −11.78 to −6.01) while the changes were not obvious after CLST with previous treatment. The scores and frequency of fourth evaluation showed that there was no significant increase or decrease in both the 2 groups. Besides, we found that the mean scores of HIT-6 for all participants, compared with the baseline, were decreased significantly after the 3 round treatments (P(3A) = 0.01 < 0.05, 95% CI, −13.12 to −6.4; P(3B) = 0.01 < 0.05, CI, −12.73 to −6.69). We also showed the similar result in the scores of HDI and HAMA. CONCLUSION: The results indicated that standardized CST was both effective and safe in alleviating the migraine intensity and frequency as well as the headache-related disability. Further larger research is needed. Lippincott Williams & Wilkins 2023-11-10 /pmc/articles/PMC10637508/ /pubmed/37960717 http://dx.doi.org/10.1097/MD.0000000000035431 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5300
Jiang, Guangya
Ma, Saichao
Zhao, Jinfeng
Zhang, Ming
Li, Yan
Chen, Wenli
Cui, Lin
Jia, Liuyun
Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial
title Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial
title_full Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial
title_fullStr Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial
title_full_unstemmed Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial
title_short Assessing the efficacy and safety of Craniosacral therapy for migraine: A single center randomized controlled trial
title_sort assessing the efficacy and safety of craniosacral therapy for migraine: a single center randomized controlled trial
topic 5300
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10637508/
https://www.ncbi.nlm.nih.gov/pubmed/37960717
http://dx.doi.org/10.1097/MD.0000000000035431
work_keys_str_mv AT jiangguangya assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial
AT masaichao assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial
AT zhaojinfeng assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial
AT zhangming assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial
AT liyan assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial
AT chenwenli assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial
AT cuilin assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial
AT jialiuyun assessingtheefficacyandsafetyofcraniosacraltherapyformigraineasinglecenterrandomizedcontrolledtrial